« Back to Record
Citation APA

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2017). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology, 28(1), 128-135. doi:10.1093/annonc/mdw434


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/241919

Shi, W., Jiang, T., Nuciforo, P., Hatzis, C., Holmes, E., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., Chia, S., Wardley, A., Ueno, T., Rossari, J., Eidtmann, H., Armour, A., Piccart-Gebhart, M., Rimm, D. D., Baselga, J., & Pusztai, L. (2017). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of oncology, 28(1), 128-135. doi:10.1093/annonc/mdw434